Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study
{{output}}
Background: Hidradenitis suppurativa (HS) is a disabling inflammatory skin disease. Objective: To investigate the efficacy and safety of upadac... ...
